Pharmacologic management of human immunodeficiency virus wasting syndrome

Pharmacotherapy

Volumn 34, Issue 8, 2014, Pages 868-881

  Badowski, Melissa ^a   Pandit, Neha Sheth ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

anabolic steroids; appetite stimulants; cytokine production modulators; HIV wasting; recombinant human growth hormone

Indexed keywords

ANABOLIC AGENT; APPETITE STIMULANT; DRONABINOL; HUMAN GROWTH HORMONE; MEGESTROL ACETATE; MIRTAZAPINE; OXANDROLONE; OXYMETHOLONE; TESTOSTERONE; THALIDOMIDE;

BODY COMPOSITION; BODY MASS; BODY WEIGHT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; TREATMENT INDICATION; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION; COMPLICATION; DRUG EFFECTS; HIV INFECTIONS; HIV WASTING SYNDROME; METHODOLOGY;

APPETITE STIMULANTS; BODY WEIGHT; DEPRESSION; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; WEIGHT GAIN;

EID: 84905919685     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1431     Document Type: Review

References (50)

1. Wanke C, Kotler D,. The approach to diagnosis and treatment of HIV wasting. J Acquir Immune Defic Syndr 2004; 37: 284-8.
2. Mangili A, Murman DH, Zampini AM, Wanke CA,. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for health living cohort. Clin Infect Dis 2006; 42: 836-42.
3. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C,. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 2005; 40: 70-6.
4. Kosmiski L,. Energy expenditure in HIV infection. Am J Clin Nutr 2001; 94 (suppl): 1677S-82S.
5. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA,. Counteracting muscle wasting in HIV-infected individuals. HIV Med 2006; 7: 299-310.
6. Shikuma CM, Zackin R, Sattler F, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1223-30.
7. Von Roenn JH, Murphy RL, Wegener N,. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 1990; 6 (suppl 9): 13-6.
8. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121: 400-8.
9. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121: 393-9.
10. Mwamburi DM, Gerrior J, Wilson IB, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clin Infect Dis 2004; 38: 895-902.
11. Mwamburi DM, Gerrior J, Wilson IB, et al. Combination megestrol acetate, oxandrolone, and dietary advice restores weight in human immunodeficiency virus. Nutr Clin Pract 2004; 19: 395-402.
12. Mulligan K, Zackin R, von Roenn JH, et al. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 2007; 92: 563-70.
13. Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13: 305-15.
14. Gorter R, Seefried M, Volberding P,. Dronabinol effects on weight in patients with HIV infection. AIDS 1992; 6: 127-8.
15. Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27: 827-31.
16. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.
17. DeJesus E, Rodwick BM, Bowers D, Cohen CJ, Pearce D,. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc Physicians AIDS Care 2007; 6: 95-100.
18. Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. J Acquir Immune Defic Syndr 2007; 45: 545-54.
19. Bedi G, Foltin RW, Gunderson EW, et al. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 2010; 212: 675-86.
20. Elliott AJ, Roy-Byrne PP,. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000; 20: 265-7.
21. Coodley GO, Coodley MK,. A trial of testosterone for HIV-associated weight loss. AIDS 1997; 11: 1347-52.
22. Knapp PE, Storer TW, Herbst KL, et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 2008; 294: E1135-43.
23. Engelson ES, Rabkin JG, Rabkin R, Kotler DP,. Effects of testosterone upon body composition. J Acquir Immune Defic Syndr 1996; 11: 510-1.
24. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. Ann Intern Med 1998; 129: 18-26.
25. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone. JAMA 2000; 283: 763-70.
26. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting: a randomized, controlled trial. Ann Intern Med 2000; 133: 348-55.
27. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998; 83: 2717-25.
28. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998; 83: 3155-62.
29. Dobs AS, Cofrancesco J, Nolten WE, et al. The use of transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 1999; 107: 126-32.
30. Choi HH, Gray PB, Storer TW, et al. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. J Clin Endocrinol Metab 2005; 90: 1531-41.
31. Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fast mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007; 92: 1049-57.
32. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R,. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10: 1657-62.
33. Shevitz AH, Wilson IB, McDermott AY, et al. A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting. J Acquir Immune Defic Syndr 2005; 38: 399-406.
34. Grunfeld C, Kotler D, Dobs A, Glesby M, Bhasin S,. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 2006; 41: 304-14.
35. Hengge UR, Stocks K, Wiehler H, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS 2003; 17: 699-710.
36. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M,. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77: 956-62.
37. Krentz AJ, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6: 245-51.
38. Schambalen M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996; 125: 873-82.
39. Moyle GJ, Daar ES, Gertner JM, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35: 367-75.
40. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 239-52.
41. Esposito JG, Thomas SG, Kingdon L, Ezzat S,. Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. Am J Physiol Endocrinol Metab 2005; 289: E494-503.
42. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16: 1345-55.
43. Bristol-Myers Squibb Company. Megace (megestrol acetate) package insert. Princeton, NJ; 2012.
44. PAR Pharmaceutical Companies, Inc. Megace ES (megestrol acetate) package insert. Spring Valley, NY; 2010.
45. Abbott. Marinol (dronabinol) package insert. North Chicago, IL; 2010.
46. Merck & Co., Inc. Remeron (mirtazapine) package insert. White Station, NJ; 2011.
47. Gooren LJG, Bunck MCM,. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861-91.
48. Savient Pharmaceuticals, Inc. Oxandrin (oxandrolone tablets) package insert. East Brunswick, NJ; 2008.
49. Alaven Pharmaceutical. Anadrol-50 (oxymetholone) package insert. Marietta, GA; 2006.
50. EMD Serono, Inc. Serostim (somatropin) package insert. Rockland, MA; 2012.